Zealand shares fall over 30% as petrelintide posts 10.7% weight loss
The amylin analog, partnered with Roche, trailed Eli Lilly's amylin candidate, which reached up to 20.1% weight loss in a comparable mid-stage trial.
PR
By Priya Raman · Science Reporter
Mar 6 03:00 ETSource: The Independent
The wire
- 01Mid-stage results for petrelintide showed up to 10.7% body weight loss over 42 weeks in 493 participants, sending Zealand Pharma shares down more than 30% and wiping 8.3 billion Danish crowns off its market value.
- 02Amylin analogs are the next peptide class after incretins, and the readout sets an efficacy bar clinicians and operators will weigh against tirzepatide and Lilly's eloralintide.
- 03A Jefferies analyst said the drug showed Wegovy-like efficacy with placebo-like tolerability but is likely seen as second-best for now; these are Phase 2 data and cross-trial comparisons are not head-to-head.
From the source
Read at independent.co.ukZealand Pharma: Obesity drug trial failure sends biotech firm’s shares into record decline
Shares in Danish biotech firm Zealand Pharma plummeted over 30 per cent on Friday, putting the company on track for its worst trading day on record.